Rational Design of α-Helix-Stabilized Exendin-4 Analogues

Rovó, Petra and Farkas, Viktor and Stráner, Pál and Szabó, Mária and Jermendy, Ágnes and Hegyi, Orsolya and Tóth, Gábor K. and Perczel, András (2014) Rational Design of α-Helix-Stabilized Exendin-4 Analogues. BIOCHEMISTRY, 53. pp. 3540-3552. ISSN 0006-2960

Preview

Text Rovo.pdf - Draft Version Available under License Creative Commons Attribution Non-commercial. Download (1MB) | Preview

Abstract

Exendin-4 (Ex4) is a potent glucagon-like peptide-1 receptor agonist, a drug regulating the plasma glucose level of patients suffering from type 2 diabetes. The molecule’s poor solubility and its readiness to form aggregates increase the likelihood of unwanted side effects. Therefore, we designed Ex4 analogues with improved structural characteristics and better water solubility. Rational design was started from the parent 20-amino acid, well-folded Trp cage (TC) miniprotein and involved the step-by-step N-terminal elongation of the TC head, resulting in the 39-amino acid Ex4 analogue, E19. Helical propensity coupled to tertiary structure compactness was monitored and quantitatively analyzed by electronic circular dichroism and nuclear magnetic resonance (NMR) spectroscopy for the 14 peptides of different lengths. Both 15N relaxation- and diffusion-ordered NMR measurements were established to investigate the inherent mobility and self-association propensity of Ex4 and E19. Our designed E19 molecule has the same tertiary structure as Ex4 but is more helical than Ex4 under all studied conditions; it is less prone to oligomerization and has preserved biological activity. These conditions make E19 a perfect lead compound for further drug discovery. We believe that this structural study improves our understanding of the relationship between local molecular features and global physicochemical properties such as water solubility and could help in the development of more potent Ex4 analogues with improved pharmacokinetic properties.

Actions (login required)

Edit Item